Drug profile · INN
rifampin
RIFADIN
rifampin (RIFADIN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — rifampin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
rifampin (RIFADIN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA-directed RNA polymerase inhibitor
Primary target: Bacterial DNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rifampin?
rifampin (RIFADIN) is a bacterial dna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for rifampin?
RIFADIN is a marketed brand name for rifampin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rifampin?
rifampin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.